BioTechnology Congress
News | 24 May 2012
I discovered one important thing attending the recent 2012 Bio Technology and Industrial Bio Congress event held in Orlando, Fl. I learned that I am neither a biologist nor a chemist. That should have been obvious to me, as I so often don't understand ...
Click on the link to read the full article at Manufacturing.net
(This link will open in a new window)
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
